glp 1 agonist exenatide PDB-101: Molecule of the Month: GLP-1 Receptor Agonists GLP-1 Receptor Agonists Explained for

Hypoglycemia is an insulin risk, not typically a GLP-1 risk

GLP-1 Receptor Agonists: The Foundation of Modern Weight Loss Medications GLP-1 receptor agonists are synthetic compounds that mimic the effects of GLP-1 but with much longer half-lives, allowing for daily or even weekly dosing

Its presence in supplement manufacturing facilities creates cross-contamination risk even when not intentionally added to formulations

The time it took these patients to develop PDR was 325 days in the GLP-1 receptor agonist group and 232 days in the control group

Recognizing obesity as a chronic disorder underscores the need for long-term pharmacological treatment, similar to the approach used for managing type 2 diabetes or hypertension to achieve optimal control

Long-term Safety Considerations The long-term safety profile observed in the SELECT study is consistent with previously reported semaglutide studies, with no new safety concerns identified for once-weekly semaglutide 2.4 mg [54]